Phase II Trial of EOquin in High-risk Superficial Bladder Cancer
NCT00141531
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
53
Enrollment
INDUSTRY
Sponsor class
Conditions
Bladder Neoplasms
Interventions
DRUG:
Apaziquone
Sponsor
Spectrum Pharmaceuticals, Inc